Iterum Therapeutics plc (ITRMF) Amortization of Deferred Charges (2018 - 2025)

Iterum Therapeutics has reported Amortization of Deferred Charges for 8 years, with the latest figure at $194000.0 in Q1 2025.

• On a quarterly basis, Amortization of Deferred Charges fell 65.91% year-over-year to $194000.0 in Q1 2025; TTM through Sep 2025 was $769000.0, a 66.55% decrease from a year earlier, with the FY2024 full-year figure at $2.3 million, down 2.18% from the prior year.
• Amortization of Deferred Charges was $194000.0 for Q1 2025 at Iterum Therapeutics, down from $575000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $2.4 million in Q1 2021, with the low at $194000.0 in Q1 2025.
• Average Amortization of Deferred Charges over 5 years is $657941.2, with a median of $584000.0 recorded in 2022.
• The largest YoY upside for Amortization of Deferred Charges was 46.96% in 2021 against a maximum downside of 85.18% in 2021.
• Over 5 years, Amortization of Deferred Charges stood at $461000.0 in 2021, then rose by 27.98% to $590000.0 in 2022, then decreased by 0.68% to $586000.0 in 2023, then retreated by 1.88% to $575000.0 in 2024, then tumbled by 66.26% to $194000.0 in 2025.
• The last three Amortization of Deferred Charges figures came in at $194000.0 (Q1 2025), $575000.0 (Q4 2024), and $575000.0 (Q3 2024), per Business Quant data.